Full Press Release Details
SAN FRANCISCO , March 1, 2017 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR ) today announced five data presentations will be delivered at the upcoming American Association for Cancer Research (AACR) Annual Meeting, which will be held April 1-5, 2017 at the Walter E. Washington Convention Center in Washington, D.C. Researchers will present new preclinical data on NKTR-214, the Company's immuno-stimulatory CD122-biased agonist, as well as on NKTR-255, the Company's IL-15 therapeutic candidate.
Details of the poster presentations are as follows: Abstract 1598/Poster 6: " Single agent NKTR-214, a biased IL2 pathway agonist, increases immune cell infiltrates in brain tumors and prolongs survival in rodent (rattus) glioblastoma (GBM) " Session: Cytokines: The First Modern Immunotherapies Date and Time: Monday, April 3, 2017 , 8:00 AM - 12:00 PM Eastern Time Location: Convention Center, Halls A-C, Poster Section 26
Abstract 1603/Poster 11: " NKTR-255 engages the IL-15 pathway driving CD8 T cell survival and CD8 memory T cell proliferation " Session: Cytokines: The First Modern Immunotherapies Date and Time: Monday, April 3, 2017 , 8:00 AM – 12:00 PM Eastern Time Location: Convention Center, Halls A-C, Poster Section 26
Abstract 1604/Poster 12: " NKTR-214 Synergizes with Radiotherapy to Drive Tumor Regression" Session: Cytokines: The First Modern Immunotherapies Date and Time: Monday, April 3, 2017 , 8:00 AM – 12:00 PM Eastern Time Location: Convention Center, Halls A-C, Poster Section 26
Abstract 1617/Poster 25: " Mechanistic modeling of a new kinetically-controlled CD122 agonist for cancer immunotherapy: NKTR-214 pharmacokinetics, pharmacodynamics, and receptor pharmacology " Session: Cytokines: The First Modern Immunotherapies Date and Time: Monday, April 3, 2017 , 8:00 AM – 12:00 PM Eastern Time Location: Convention Center, Halls A-C, Poster Section 26
Abstract 2671/Poster 30: " Antitumor activity of NKTR-214 in combination with Adopted Cell Transfer (ACT) in an aggressive murine melanoma " Session: Immune Response to Hematopoietic Tumors: New Development in Tumor Immunology Date and Time: Monday, April 3, 2017 1:00 PM – 5:00 PM Eastern Time Location: Convention Center, Halls A-C, Poster Section 26
About Nektar Therapeutics
Nektar Therapeutics is a research-based development stage biopharmaceutical company whose mission is to discover and develop innovative medicines to address the unmet medical needs of patients. Our R&D pipeline of new investigational medicines includes treatments for cancer, auto-immune disease and chronic pain. We leverage Nektar's proprietary and proven chemistry platform in the discovery and design of our new therapeutic candidates. Nektar is headquartered in San Francisco, California , with additional operations in Huntsville, Alabama and Hyderabad, India . Further information about the company and its drug development programs and capabilities may be found online at http://www.nektar.com .
For Investors: Jennifer Ruddock of Nektar Therapeutics 415-482-5585
Jodi Sievers of Nektar Therapeutics 415-482-5593
For Media: Dan Budwick of Pure Communications 973-271-6085 [email protected]
SOURCE Nektar Therapeutics